© 2022 BioMarin. All rights reserved.

First Gene Therapy for Adults with Severe Hemophilia A, BioMarin’s ROCTAVIAN™ (valoctocogene roxaparvovec), Approved by European Commission (EC) Webcast
 Wednesday, August 24, 2022
 5:00pm PDT